191 related articles for article (PubMed ID: 26517656)
1. A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old.
Collaborative Group for Studies of Yellow Fever Vaccine
Mem Inst Oswaldo Cruz; 2015 Sep; 110(6):771-80. PubMed ID: 26517656
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
Collaborative Group for Studies with Yellow Fever Vaccine
Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
[TBL] [Abstract][Full Text] [Related]
3. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L;
Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779
[TBL] [Abstract][Full Text] [Related]
4. 17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.
Campi-Azevedo AC; de Araújo-Porto LP; Luiza-Silva M; Batista MA; Martins MA; Sathler-Avelar R; da Silveira-Lemos D; Camacho LA; de Menezes Martins R; de Lourdes de Sousa Maia M; Farias RH; da Silva Freire M; Galler R; Homma A; Ribeiro JG; Lemos JA; Auxiliadora-Martins M; Caldas IR; Elói-Santos SM; Teixeira-Carvalho A; Martins-Filho OA
PLoS One; 2012; 7(12):e49828. PubMed ID: 23251351
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial.
Camacho LA; Freire Mda S; Leal Mda L; Aguiar SG; Nascimento JP; Iguchi T; Lozana Jde A; Farias RH;
Rev Saude Publica; 2004 Oct; 38(5):671-8. PubMed ID: 15499438
[TBL] [Abstract][Full Text] [Related]
6. Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.
Campi-Azevedo AC; Reis LR; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Antonelli LR; Fonseca CT; Costa-Pereira C; Souza-Fagundes EM; da Costa-Rocha IA; Mambrini JVM; Lemos JAC; Ribeiro JGL; Caldas IR; Camacho LAB; Maia MLS; de Noronha TG; de Lima SMB; Simões M; Freire MDS; Martins RM; Homma A; Tauil PL; Vasconcelos PFC; Romano APM; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA
Front Immunol; 2019; 10():2192. PubMed ID: 31616412
[TBL] [Abstract][Full Text] [Related]
7. Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.
da Costa-Rocha IA; Machado KLLL; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; de Lima SMB; Miranda EH; Trindade GF; Casagrande TZ; Miyamoto ST; Deotti SC; Barbosa RVR; Rocha PCM; Serrano EV; Dinis VG; Gouvêa SA; Gavi MBRO; da Silva LB; Duque RH; Gianordoli APE; Bissoli MF; Gouvea MDPG; Pinto-Neto LFDS; Burian APN; Fantinato FFST; Pileggi GS; da Mota LMH; Valim V; Martins-Filho OA
Sci Rep; 2021 May; 11(1):10431. PubMed ID: 34001945
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.
Juan-Giner A; Kimathi D; Grantz KH; Hamaluba M; Kazooba P; Njuguna P; Fall G; Dia M; Bob NS; Monath TP; Barrett AD; Hombach J; Mulogo EM; Ampeire I; Karanja HK; Nyehangane D; Mwanga-Amumpaire J; Cummings DAT; Bejon P; Warimwe GM; Grais RF
Lancet; 2021 Jan; 397(10269):119-127. PubMed ID: 33422245
[TBL] [Abstract][Full Text] [Related]
9. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
Juan-Giner A; Namulwana ML; Kimathi D; Grantz KH; Fall G; Dia M; Bob NS; Sall AA; Nerima C; Sahani MK; Mulogo EM; Ampeire I; Hombach J; Nanjebe D; Mwanga-Amumpaire J; Cummings DAT; Bejon P; Warimwe GM; Grais RF
Lancet Infect Dis; 2023 Aug; 23(8):965-973. PubMed ID: 37127047
[TBL] [Abstract][Full Text] [Related]
11. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial.
Camacho LA; de Aguiar SG; Freire Mda S; Leal Mda L; do Nascimento JP; Iguchi T; Lozana JA; Farias RH;
Rev Saude Publica; 2005 Jun; 39(3):413-20. PubMed ID: 15997317
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Final Report.
Casey RM; Harris JB; Ahuka-Mundeke S; Dixon MG; Kizito GM; Nsele PM; Umutesi G; Laven J; Kosoy O; Paluku G; Gueye AS; Hyde TB; Ewetola R; Sheria GKM; Muyembe-Tamfum JJ; Staples JE
N Engl J Med; 2019 Aug; 381(5):444-454. PubMed ID: 29443626
[TBL] [Abstract][Full Text] [Related]
13. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys.
Marchevsky RS; Freire MS; Coutinho ES; Galler R
Virology; 2003 Nov; 316(1):55-63. PubMed ID: 14599790
[TBL] [Abstract][Full Text] [Related]
14. Seroconversion and antibody persistence after yellow fever vaccination in people living with HIV: impact of baseline HIV viral load and yellow fever seropositivity.
Martin C; Florence E; Domingo C; Delforge M; De Wit S; Dauby N
J Travel Med; 2022 Dec; 29(8):. PubMed ID: 35285913
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review.
Martin C; Domingo C; Bottieau E; Buonfrate D; De Wit S; Van Laethem Y; Dauby N
Clin Microbiol Infect; 2021 Jul; 27(7):958-967. PubMed ID: 33813107
[TBL] [Abstract][Full Text] [Related]
16. Booster dose after 10 years is recommended following 17DD-YF primary vaccination.
Campi-Azevedo AC; Costa-Pereira C; Antonelli LR; Fonseca CT; Teixeira-Carvalho A; Villela-Rezende G; Santos RA; Batista MA; Campos FM; Pacheco-Porto L; Melo Júnior OA; Hossell DM; Coelho-dos-Reis JG; Peruhype-Magalhães V; Costa-Silva MF; de Oliveira JG; Farias RH; Noronha TG; Lemos JA; von Doellinger Vdos R; Simões M; de Souza MM; Malaquias LC; Persi HR; Pereira JM; Martins JA; Dornelas-Ribeiro M; Vinhas Ade A; Alves TR; Maia Mde L; Freire Mda S; Martins Rde M; Homma A; Romano AP; Domingues CM; Tauil PL; Vasconcelos PF; Rios M; Caldas IR; Camacho LA; Martins-Filho OA
Hum Vaccin Immunother; 2016; 12(2):491-502. PubMed ID: 26360663
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
[TBL] [Abstract][Full Text] [Related]
18. 17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil.
Campi-Azevedo AC; Peruhype-Magalhāes V; Coelho-Dos-Reis JG; Antonelli LR; Costa-Pereira C; Speziali E; Reis LR; Lemos JA; Ribeiro JGL; Bastos Camacho LA; de Sousa Maia ML; Barbosa de Lima SM; Simões M; de Menezes Martins R; Homma A; Cota Malaquias LC; Tauil PL; Costa Vasconcelos PF; Martins Romano AP; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
Emerg Infect Dis; 2019 Aug; 25(8):1511-1521. PubMed ID: 31298654
[TBL] [Abstract][Full Text] [Related]
19. Immune response to co-administration of measles, mumps, and rubella (MMR), and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina.
Vizzotti C; Harris JB; Aquino A; Rancaño C; Biscayart C; Bonaventura R; Pontoriero A; Baumeister E; Freire MC; Magariños M; Duarte B; Grant G; Reef S; Laven J; Wannemuehler KA; Alvarez AMR; Staples JE
BMC Infect Dis; 2023 Mar; 23(1):165. PubMed ID: 36932346
[TBL] [Abstract][Full Text] [Related]
20. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
